Clinical Trials Logo

Lung Carcinoid Tumor clinical trials

View clinical trials related to Lung Carcinoid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT04085081 Withdrawn - Clinical trials for Lung Non-Small Cell Carcinoma

Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers

Start date: May 15, 2021
Phase: N/A
Study type: Interventional

This trial studies whether a telephone-based physical activity intervention before and after lung cancer surgery can be provided to older patients and their caregivers. The trial also aims to understand whether patients and family caregivers will be satisfied with the intervention. Participating in physical activity such as walking before and after lung cancer surgery may improve functional status and recovery in older patients and their family caregivers.

NCT ID: NCT03923777 Enrolling by invitation - Clinical trials for Stage IA Non-small Cell Lung Cancer

Active Surveillance in Early Lung Cancer

ACTION-Lung
Start date: July 31, 2018
Phase: N/A
Study type: Interventional

Cancer patients are often given the choice of delaying or avoiding treatment as one of their options. However, there is not much information guiding lung cancer patients and their clinicians regarding this approach. Active surveillance is a way of either delaying or avoiding treatment and its possible side effects through carefully watching for changes in the tumor and considering treatment if there is progression. The purpose of this research study is to evaluate active surveillance and ways to better understand if and when to treat patients with stage IA lung cancer.

NCT ID: NCT03707925 Terminated - Clinical trials for Stage IV Lung Cancer AJCC v8

Bronchoscopic Laser Ablation of Peripheral Lung Tumors

Start date: September 18, 2018
Phase: N/A
Study type: Interventional

As our population ages and we diagnose early lung cancer in patients who cannot undergo surgery due to multiple medical conditions, there is growing interest in minimally invasive modalities to treat these tumors. In this study we are assessing the ability of bronchoscopic laser ablation to kill the cancer cells in these tumors. Patients will undergo bronchoscopy (a tube-like instrument inserted through the mouth to view the inside of the trachea, air passages, and lungs). A thin catheter will be passed through the wind-pipes and into the lung tumor with computed tomography guidance. A laser probe is then passed through this catheter and it is used to destroy the tumor with heat. Patients will then undergo lung surgery with resection of the tumor, and the resected specimen will be reviewed to describe the amount of tumor-kill produced by the laser.

NCT ID: NCT01548482 Completed - Clinical trials for Stage IV Renal Cell Cancer

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Start date: March 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of trebananib and temsirolimus when given together in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trebananib with temsirolimus may be an effective treatment for solid tumors.

NCT ID: NCT01204476 Completed - Paraganglioma Clinical Trials

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer. Monoclonal antibodies, such as cixutumumab, may find tumor cells and help carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Octreotide acetate may interfere with the growth of tumor cells and slow the growth of neuroendocrine cancer. Giving cixutumumab together with everolimus and octreotide acetate may be a better treatment for neuroendocrine cancer.

NCT ID: NCT01010126 Completed - Clinical trials for Recurrent Ovarian Carcinoma

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Start date: September 8, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

NCT ID: NCT00454363 Completed - Clinical trials for Pancreatic Polypeptide Tumor

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.